{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:33:09Z","timestamp":1788582789202,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>This study provides a comprehensive analysis of early-stage resectable non-small cell lung cancer (NSCLC) in Hungary, investigating incidence rates, demographic trends, treatment patterns and survival outcomes. We used data from the National Health Insurance Fund (NHIF) spanning 2013\u20132022, and we analyzed 6,571 patients with available NSCLC histology and no metastasis, who underwent curative surgery within 6\u00a0months of diagnosis, and evaluated epidemiological trends and the use of neoadjuvant and adjuvant therapies. For the efficacy analysis, we narrowed the patient cohort to 5,494 patients diagnosed and treated between 2013 and 2019 with at least three-year follow-up data. Key endpoints included overall survival (OS) and disease-free survival (DFS), inferred via time to first subsequent therapy (TFST). Our results revealed a gradual decline in early-stage resectable NSCLC diagnoses, with a significant drop in 2020, likely linked to COVID-19 restrictions. Older age groups (66\u201375 years) represented a growing proportion of cases, reflecting shifting demographic trends. Among patients with EGFR mutations receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, OS significantly improved compared to those not receiving EGFR-TKI therapy, who are assumed to have wild-type EGFR status (HR = 0.58 (95% CI: 0.47\u20130.72), p &amp;lt; 0.0001). These findings underscore the importance of early detection, comprehensive biomarker testing and targeted therapies in improving outcomes for resectable NSCLC patients. Future studies with extended follow-up and integration of broader clinical data, including staging and patient comorbidities, are warranted to optimize therapeutic strategies.<\/jats:p>","DOI":"10.3389\/pore.2025.1612152","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:10:08Z","timestamp":1753679408000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Early-stage resectable non-small cell lung cancer in Hungary"],"prefix":"10.3389","volume":"31","author":[{"given":"Gabriella","family":"G\u00e1lffy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"H\u00e9cz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"Bujdos\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"G\u00e1sp\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"Korompay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Hoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Sz\u00e9cs\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Blasszauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Reibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Bogos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Ag\u00f3cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"R\u00e9nyi-V\u00e1mos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"M\u00f3rocz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clinicians"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"B5","first-page":"345","article-title":"A korai st\u00e1dium\u00fa nem kissejtes t\u00fcd\u0151r\u00e1k kivizsg\u00e1l\u00e1si folyamat\u00e1nak hazai konszenzusa a nemzetk\u00f6zi ir\u00e1nyelvek figyelembev\u00e9tel\u00e9vel","volume":"77","author":"Bogos","year":"2024","journal-title":"Medicina Thoracalis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1611635","DOI":"10.3389\/pore.2024.1611635","article-title":"HUNCHEST projects\u2014advancing low-dose CT lung cancer screening in Hungary","volume":"30","author":"Kerpel-Fronius","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00330-023-10379-8","article-title":"HUNCHEST-II contributes to a shift to earlier-stage lung cancer detection: final results of a nationwide screening program","volume":"34","author":"Kerpel-Fronius","year":"2024","journal-title":"Eur Radiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jtho.2019.11.001","article-title":"Lung cancer in Hungary","volume":"15","author":"Bogos","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1609916","DOI":"10.3389\/pore.2021.1609916","article-title":"Significant regional differences in lung cancer incidence in Hungary: epidemiological study between 2011 and 2016","volume":"27","author":"G\u00e1lffy","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1611754","DOI":"10.3389\/pore.2024.1611754","article-title":"Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources","volume":"30","author":"G\u00e1lffy","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3389\/fonc.2019.01051","article-title":"Revising incidence and mortality of lung cancer in central europe: an epidemiology review from Hungary","volume":"9","author":"Bogos","year":"2019","journal-title":"Front Oncol"},{"key":"B13","first-page":"175","article-title":"A t\u00fcd\u0151r\u00e1k hazai epidemiol\u00f3giai adatai \u00faj megk\u00f6zel\u00edt\u00e9sben","volume-title":"Magyar onkol\u00f3gia","author":"Bogos","year":"2020"},{"key":"B14","unstructured":"Vok\u00f3 Zolt\u00e1n: can we see the forest from the numbers? Let us look beyond the statistics through the example of lung cancer\n          \n          \n          2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"603937","DOI":"10.3389\/pore.2021.603937","article-title":"Improvement in lung cancer survival: 6-year trends of overall survival at Hungarian patients diagnosed in 2011\u20132016","volume":"27","author":"Bogos","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1610041","DOI":"10.3389\/pore.2021.1610041","article-title":"Increase in the length of lung cancer patient pathway before first-line therapy: a 6-year nationwide analysis from Hungary","volume":"27","author":"Kiss","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"New Engl J Med"},{"key":"B18","volume-title":"Kor\u00e1nyi Bulletin","year":"2023"},{"key":"B19","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol official J Eur Soc Med Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12885-018-4023-4","article-title":"NSCLC molecular testing in Central and Eastern European countries","volume":"18","author":"Ryska","year":"2018","journal-title":"BMC Cancer"},{"key":"B21","volume-title":"Snomed CT - NHS england digital","year":""},{"key":"B22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1556\/650.2022.32573","article-title":"Comparison of Hungarian central statistical office\u2019s causes of death data with the database of the Hungarian national cancer registry","volume":"163","author":"Weber","year":"2022","journal-title":"Orv Hetil"},{"key":"B23","doi-asserted-by":"publisher","first-page":"102306","DOI":"10.1016\/j.canep.2022.102306","article-title":"Evaluation of data quality at the Hungarian national cancer registry, 2000-2019","volume":"82","author":"Weber","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/cam4.4946","article-title":"Characteristics and overall survival of patients with early-stage non-small cell lung cancer: a cohort study in Denmark","volume":"12","author":"Ehrenstein","year":"2023","journal-title":"Cancer Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"909064","DOI":"10.3389\/fonc.2022.909064","article-title":"Diagnostic-therapeutic pathway and outcomes of early stage NSCLC: a focus on EGFR testing in the real-world","volume":"12","author":"Pasello","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.ctarc.2023.100742","article-title":"Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: a retrospective observational study","volume":"36","author":"Shah","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"B27","unstructured":"Daganatos betegek onkol\u00f3giai ell\u00e1t\u00e1s\u00e1hoz sz\u00fcks\u00e9ges molekul\u00e1ris patol\u00f3giai vizsg\u00e1latok elj\u00e1r\u00e1srendj\u00e9nek meghat\u00e1roz\u00e1sa"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1612152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:10:09Z","timestamp":1753679409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1612152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":27,"alternative-id":["10.3389\/pore.2025.1612152"],"URL":"https:\/\/doi.org\/10.3389\/pore.2025.1612152","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"article-number":"1612152"}}